HIV-vaccines: lessons learned and the way forward

1. UNAIDS. AIDS epidemic update: December 2009.Search in Google Scholar

2. Rojanapithayakorn W. The 100% condom use programme in Asia. Reprod Health Matters. 2006; 14: 41-52.10.1016/S0968-8080(06)28270-3Open DOISearch in Google Scholar

3. Punyacharoensin N, Viwatwongkasem C. Trends in three decades of HIV/AIDS epidemic in Thailand by nonparametric backcalculation method. AIDS. 2009; 23:1143-52.10.1097/QAD.0b013e32832baa1cSearch in Google Scholar

4. Johnston MI, Fauci AS. An HIV vaccine-challenges and prospects. N Engl J Med. 2008; 359:888-90.10.1056/NEJMp0806162Search in Google Scholar

5. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science. 2008; 321:530-2.10.1126/science.1161000Search in Google Scholar

6. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008; 455:613-9.10.1038/nature07352Search in Google Scholar

7. Berkley SF, Koff WC. Scientific and policy challenges to development of an AIDS vaccine. Lancet. 2007; 370: 94-101.10.1016/S0140-6736(07)61054-XSearch in Google Scholar

8. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol. 2006; 7:19-23.10.1038/ni129616357854Search in Google Scholar

9. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191:654-65.10.1086/42840415688278Search in Google Scholar

10. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661-71.10.1086/50874817109337Search in Google Scholar

11. Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008; 320:760-4.10.1126/science.115262218467582Search in Google Scholar

12. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med. 2004; 10:769-71.10.1038/nm0804-76915286768Search in Google Scholar

13. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat Med. 2004; 10:806-10.10.1038/nm0804-80615286782Search in Google Scholar

14. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD81 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68, 6103-10.10.1128/jvi.68.9.6103-6110.1994Search in Google Scholar

15. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008; 122:3-9.10.1016/j.jaci.2008.03.036301457318468671Search in Google Scholar

16. Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis. 2007; 4:546-50.10.1086/51090917230414Search in Google Scholar

17. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, Nabel GJ, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med. 2006; 203: 1533-41.10.1084/jem.20060657211831416735692Search in Google Scholar

18. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol. 2006; 80:5875-85.10.1128/JVI.00171-06147261216731926Search in Google Scholar

19. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol. 2009; 83:8300-14. \10.1128/JVI.00114-09273816019439471Open DOISearch in Google Scholar

20. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008; 14:617-21.10.1038/nm.f.1759369785318535579Search in Google Scholar

21. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997; 11 (Suppl A): S127-37.Search in Google Scholar

22. Fast PE. Recent trends in clinical trials of vaccines to prevent HIV/AIDS. Curr Opin HIV AIDS. 2006; 1: 267-71.10.1097/01.COH.0000232340.77790.7a19372820Search in Google Scholar

23. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology. 2008; 381:106-15.10.1016/j.virol.2008.08.019478277618793787Search in Google Scholar

24. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Human Vaccines. 2009; 5:1-5.10.4161/hv.969319786840Search in Google Scholar

25. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008; 46:1769-81.10.1086/58799318433307Search in Google Scholar

26. Spearman P: HIV Vaccine Development. Lessons from the Past and Promise for the Future. Curr HIV Res. 2003; 1:101-20.10.2174/157016203335209315043215Search in Google Scholar

27. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007; 25:4085-92.10.1016/j.vaccine.2007.02.05017391815Search in Google Scholar

28. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205:63-77.10.1084/jem.20071331223437118195071Search in Google Scholar

29. Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007; 45:20-7.10.1097/QAI.0b013e3180377b5b17310936Search in Google Scholar

30. Vaccari M, Mattapallil J, Song K, Tsai WP, Hryniewicz A, Venzon D, et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol. 2008; 82: 9629-38.10.1128/JVI.00893-08254695718667509Search in Google Scholar

31. Engram JC, Dunham RM, Makedonas G, Vanderford TH, Sumpter B, Klatt NR, et al. Vaccine-induced, Simian Immunodeficiency Virus-specific CD8+ T cells reduce virus replication but do not protect from Simian Immunodeficiency Virus disease progression. J Immunol. 2009; 183:706-17.10.4049/jimmunol.080374619542473Search in Google Scholar

32. Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol. 2004; 78:3930-40.10.1128/JVI.78.8.3930-3940.2004Open DOISearch in Google Scholar

33. Amara RR, Villinger F, Altman JD, Lydy SL, O’Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292:69-74.10.1126/science.292.5514.69Search in Google Scholar

34. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on ‘Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines’, 31 January-2 February 2006, IAVI, New York, USA. AIDS. 2007; 21:539-46.10.1097/QAD.0b013e328011a0c9Search in Google Scholar

35. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, testof- concept trial. Lancet. 2008; 372:1881-93.10.1016/S0140-6736(08)61591-3Search in Google Scholar

36. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a casecohort analysis. Lancet. 2008; 372:1894-905.10.1016/S0140-6736(08)61592-5Search in Google Scholar

37. Gray G. Results from the Phambili (HVTN 503) study: a multicenter phase IIB test-of-concept study of the MRKad5 HIV-1 gag/pol/nef vaccine in South Africa. Presented at AIDS Vaccine 2008, Cape Town, South Africa, October 13-16, 2008.Search in Google Scholar

38. Excler JL, Rida W, Priddy F, Fast P, Koff W. A strategy for accelerating the development of preventive AIDS vaccines. AIDS. 2007; 21:2259-63.10.1097/QAD.0b013e3282eee70c18090273Search in Google Scholar

39. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine ‘prime-boost’ phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006; 20: 1471-9.10.1097/01.aids.0000237362.26370.f816847401Search in Google Scholar

40. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med. 2009; 361:2209-20.10.1056/NEJMoa090849219843557Search in Google Scholar

41. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines. 2008; 7:311-7.10.1586/14760584.7.3.31118393601Open DOISearch in Google Scholar

42. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr. 2007; 46:48-55.10.1097/QAI.0b013e3181354bd717909315Search in Google Scholar

43. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al. Antibodydependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/ AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005; 23:2522-9.10.1016/j.vaccine.2004.10.02815752839Open DOISearch in Google Scholar

44. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661-71.10.1086/50874817109337Search in Google Scholar

45. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004; 303:316.10.1126/science.109462014726576Search in Google Scholar

46. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des. 2007; 13:213-27.10.2174/13816120777931363217269929Open DOISearch in Google Scholar

47. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008; 72:54-84.10.1128/MMBR.00006-08Open DOISearch in Google Scholar

48. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature.2007; 446:1038-45.10.1038/nature0581817460665Search in Google Scholar

49. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009; 83: 7337-48.10.1128/JVI.00110-09270477819439467Search in Google Scholar

50. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326:285-9.10.1126/science.1178746333527019729618Search in Google Scholar

51. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009; 15:901-6.10.1038/nm.1967272317719448633Open DOISearch in Google Scholar

52. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther. 2008; 19:663-9.10.1089/hum.2008.033294063418549307Open DOISearch in Google Scholar

53. Sharpe S, Polyanskaya N, Dennis M, Sutter G, Hanke T, Erfle V, et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol. 2001; 82:2215-23.10.1099/0022-1317-82-9-221511514732Search in Google Scholar

54. Koff WC, Parks CL, Berkhout B, Ackland J, Noble S, Gust ID. Replicating viral vectors as HIV vaccines summary report from IAVI sponsored satellite symposium, International AIDS Society Conference, July 22, 2007. Biologicals. 2008; 36:277-86.10.1016/j.biologicals.2008.04.00418555698Search in Google Scholar

55. Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr HIV Res. 2007; 5:97-107.10.2174/15701620777931626017266561Search in Google Scholar

56. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol. 2006; 6:417-23.10.1038/nri184016622477Open DOISearch in Google Scholar

57. D’Souza MP, Altfeld M. Measuring HIV specific T cell immunity: how valid are current assays? J Infect Dis. 2008; 197:337-9.10.1086/525288Search in Google Scholar

58. Chuenchitra T, Sukwit S, Gaywee J, Viputtikul K, Eamsila C, Tabprasit S, et al. The development of HIV research laboratories in the Royal Thai Army Medical Department. J Med Assoc Thai. 2005; 88 (Suppl 3):S317-24.Search in Google Scholar

59. Fauce SR, Yang OO, Effros RB. Autologous CD4/CD8 co-culture assay: A physiologically-relevant composite measure of CD8(+) T lymphocyte function in HIVinfected persons. J Immunol Methods. 2007; 327: 75-81.10.1016/j.jim.2007.07.017215192817716683Search in Google Scholar

60. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009; 83:3138-49.10.1128/JVI.02073-08265555819158248Open DOISearch in Google Scholar

61. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, et al. Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009; 83: 791-801. 10.1128/JVI.01672-08261236518971271Search in Google Scholar

62. Excler JL. AIDS vaccine efficacy trials: expand capacity and prioritize. ‘Throughout Africa, Asia and Latin America state-of-the-art clinics and laboratories.exist where, 4 years ago, there were none’. Expert Rev Vaccines. 2006; 5:167-70.10.1586/14760584.5.2.16716608417Search in Google Scholar

63. Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, Tamashiro H, Osmanov S; WHO-UNAIDS Regional Consultation. Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J Trop Med Public Health. 2008; 39: 766-84.Search in Google Scholar

64. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, Trichavaroj R, et al. Incidence and characterization of acute HIV-1 infection in a highrisk Thai population. J Acquir Immune Defic Syndr. 2008; 49:151-5.10.1097/QAI.0b013e318183a96d18769355Search in Google Scholar

65. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008; 5:e157; discussion e157.10.1371/journal.pmed.0050157249456218684007Open DOISearch in Google Scholar

66. Moore JP, Veazey RA, Barouch D. Can Vaccines and Microbicides be Co-developed? Presented at AIDS Vaccine 2008, Cape Town, South Africa, October 13-16, 2008. [Abstract RT01-01].Search in Google Scholar

67. Plotkin SA. Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc. 2009; 12:2.10.1186/1758-2652-12-2Search in Google Scholar